Tango Therapeutics, Inc.
TNGX
주식 순위
#4543
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and... Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
주가
$27.18
마지막 동기화: 2026-07-31
시가총액
$3.38B
변동 (1일)
-1.41%
변동 (1년)
202.34%
국가
US
거래 Tango Therapeutics, Inc. (TNGX)
카테고리
Healthcare
Tango Therapeutics, Inc. (TNGX)의 매출
Jun 2026 기준 매출 TTM: $53.81M
Tango Therapeutics, Inc.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 $53.81M입니다. 2023년에 회사는 $36.53M의 수익을 올렸으며 이는 2022년의 $24.86M 대비 증가입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Tango Therapeutics, Inc.의 수익 기록 (2019 ~ 2026)
매년 말 매출
| 연도 | 매출 | 변화 |
|---|---|---|
| 2026 (TTM) | $53.81M | 27.91% |
| 2024 | $42.07M | 15.17% |
| 2023 | $36.53M | 46.93% |
| 2022 | $24.86M | -32.89% |
| 2021 | $37.04M | 383.83% |
| 2020 | $7.66M | -68.94% |
| 2019 | $24.65M | 0.00% |
유사 기업 또는 경쟁사의 매출
| 회사 | 매출 | 매출 차이 | 국가 |
|---|---|---|---|
| $12.62B | 23,360.44% |
US
|
|
| $2.23B | 4,040.42% |
US
|
|
| $15.74B | 29,158.57% |
AU
|
|
| $6.02B | 11,089.70% |
NL
|
|
| - | - |
CH
|
